The U.K. Department of Health is trying to salvage two value metrics from its abandoned value-based pricing system by incorporating them into NICE's existing health technology appraisal process. In theory the new methodology would raise the cost-effectiveness threshold for some drugs when there is a high burden of illness or wider societal impact. But the head of NICE's HTA process cautions it's too early to speculate how many drugs will actually qualify for a meaningfully higher threshold.

The value-based pricing scheme was intended to promote innovation and increase access to new medicines by linking the value provided by a drug to its price on the NHS. But efforts to implement the scheme were abandoned last year after industry and government were unable to conclude negotiations on how it would work.